Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 4, 2008, Pages 914-918

  Wyen, Christoph ^a   Hendra, Heidy ^a   Vogel, Martin ^b   Hoffmann, Christian ^c,n   Knechten, Heribert ^d   Brockmeyer, Norbert H ^e   Bogner, Johannes R ^f   Rockstroh, Jürgen ^b   Esser, Stefan ^g   Jaeger, Hans ^h   Harrer, Thomas ⁱ   Mauss, Stefan ^j   van lunzen, Jan ^k   Skoetz, Nicole ^a   Jetter, Alexander ^l   Groneuer, Christiane ^a   Fätkenheuer, Gerd ^a   Khoo, Saye H ^m   Egan, Deirdre ^m   Back, David J ^m   Owen, Andrew ^m   more..

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c IPM   (Germany)

^d Praxen Zentrum Blondelstrasse   (Germany)

^e ST JOSEF HOSPITAL   (Germany)

^f UNIVERSITY OF MUNICH   (Germany)

^g UNIVERSITY OF DUISBURG ESSEN   (Germany)

^h HIV Research and Clinical Care Centre Munich   (Germany)

ⁱ UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^j Gemeinschaftspraxis Mauss   (Germany)

^k UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^l UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^m UNIVERSITY OF LIVERPOOL   (United Kingdom)

ⁿ UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

more..

Author keywords

Drug disposition; Metabolism; NNRTIs; Pharmacogenetics; Pharmacokinetics

Indexed keywords

CYTOCHROME P450 2B6; CYTOSINE; EFAVIRENZ; NEVIRAPINE; THYMINE;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CAUCASIAN; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; ETHNIC DIFFERENCE; ETHNICITY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; GERMANY; HAPLOTYPE; HETEROZYGOSITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOZYGOSITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEGRO; PHARMACOGENETICS; REAL TIME POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; UNSPECIFIED SIDE EFFECT;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGE FACTORS; AGED; AGED, 80 AND OVER; ARYL HYDROCARBON HYDROXYLASES; BENZOXAZINES; BODY MASS INDEX; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEVIRAPINE; OXIDOREDUCTASES, N-DEMETHYLATING; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 41149092923     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn029     Document Type: Article

References (17)

1. Owen A, Pirmohamed M, Khoo SH et al. Pharmacogenetics of HIV therapy. Pharmacogenet Genomics 2006; 16: 693-703.
2. Lang T, Klein K, Fischer J et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001; 11: 399-415.
3. Haas DW, Bartlett JA, Andersen JW et al. Pharmacogenetics of nevirapine-associated hepatotoxicity: An Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis 2006; 43: 783-6.
4. Haas DW, Ribaudo HJ, Kim RB et al. Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS Clinical Trials Group study. AIDS 2004; 18: 2391-400.
5. Ribaudo HJ, Haas DW, Tierney C et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: An Adult AIDS Clinical Trials Group Study. Clin Infect Dis 2006; 42: 401-7.
6. Ritchie MD, Haas DW, Motsinger AA et al. Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin Infect Dis 2006; 43: 779-82.
7. Rodriguez-Novoa S, Barreiro P, Rendon A et al. Influence of 516G> T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis 2005; 40: 1358-61.
8. Rotger M, Colombo S, Furrer H et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 2005; 15: 1-5.
9. Tsuchiya K, Gatanaga H, Tachikawa N et al. Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun 2004; 319: 1322-6.
10. Gatanaga H, Hayashida T, Tsuchiya K et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin Infect Dis 2007; 45: 1230-7.
11. Klein K, Lang T, Saussele T et al. Genetic variability of CYP2B6 in populations of African and Asian origin: Allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics 2005; 15 861-73.
12. Rotger M, Tegude H, Colombo S et al. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther 2007; 81 557-66.
13. Mehlotra RK, Bockarie MJ, Zimmerman PA. CYP2B6 983T> C polymorphism is prevalent in West Africa but absent in Papua New Guinea: Implications for HIV/AIDS treatment. Br J Clin Pharmacol 2007; 64: 391-5.
14. Almond LM, Hoggard PG, Edirisinghe D et al. Intracellular plasma pharmacokinetics of efavirenz in HIV-infected individuals. J Antimicrob Chemother 2005; 56: 738-44.
15. Clarke SM, Mulcahy FM, Tjia J et al. Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. Clin Infect Dis 2001; 33: 1595-7.
16. Haas DW, Smeaton LM, Shafer RW et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/ or nelfinavir: An Adult AIDS Clinical Trials Group study. J Infect Dis 2005; 192: 1931-42.
17. Lang T, Klein K, Richter T et al. Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: Demonstration of phenotypic null alleles. J Pharmacol Exp Ther 2004; 311: 34-43.